| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 33
| Issue : 1 | Page : 6-11 |
|
|
Intraocular pressure changes after intravitreal bevacizumab or ranibizumab injection: A retrospective study
Tarannum Mansoori1, Satish Gooty Agraharam2, Sunny Manwani2, Nagalla Balakrishna3
1 Department of Glaucoma, Anand Eye Institute, Hyderabad, Telangana, India
2 Department of Retina, Anand Eye Institute, Hyderabad, Telangana, India
3 Department of Statistics, Apollo Institute of Medical Sciences and Research, Hyderabad, Telangana, India
Correspondence Address:
Tarannum Mansoori
Department of Glaucoma, Sita Lakhsmi Eye Center, Anand Eye Institute, 7.147/1, Nagendra Nagar Colony, Habsiguda, Hyderabad . 500 007, Telangana
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/JOCO.JOCO_5_20
|
|
|
Purpose: To determine intraocular pressure (IOP) changes after intravitreal bevacizumab or ranibizumab injection administered for various retinal disorders.
Methods: A retrospective chart review of 796 eyes of 574 patients receiving intravitreal ranibizumab (0.5 mg) and/or bevacizumab (1.25 mg) injection for different retinal diseases from March 2009 to December 2016 was performed. Ocular hypertension (OHT) was defined as IOP >21 mmHg or an increase in IOP of >5 mmHg from the baseline. IOP at the baseline and at various time periods after the injection was evaluated in the injected eyes and fellow control eyes.
Results: One hundred and thirty-one eyes received either a single dose of bevacizumab or ranibizumab intravitreal injection unilaterally, 222 patients received single injection in both the eyes (n = 444 eyes), and 221 eyes received multiple doses of the injection. OHT was noted in 11 eyes (1.38%), of which 3 eyes (0.38%) had transient OHT and 8 eyes (1%) had delayed and sustained OHT and among them, 3 eyes (0.4%) progressed to glaucoma. Preinjection IOP was significantly higher in the treated eyes when compared to the control untreated eyes (P = 0.006).
Conclusions: Incidence of delayed and sustained OHT is low after a single or multiple intravitreal bevacizumab and ranibizumab injections. Clinicians should be aware of possibility of OHT or glaucoma after the procedure.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
